| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American College of Clinical Pharmacology:
Symposium II
September 10, 2007 Model-Based Drug Development: Status 2007
Cosponsored by The American Society for Clinical Pharmacology and Therapeutics (ASCPT)
8:00 AM - 9:00 AM
Keynote Presentation: Transformation of the Pharmaceutical Industry: The Role of Critical Path
Andrew M. Dahlem, Ph.D., Lilly Research Laboratories,
Lise Lund Kjems, M.D., Ph.D., Novartis Institutes for BioMedical Res., Inc.,
10:00 AM - 10:45 AM
Translational PK-PD, From Animals to Man
Kathleen M. Giacomini, Ph.D.,
10:45 AM - 11:30 AM
Experience with Novel INDs and Biomarkers in Early Clinical Development
Rebecca Boyd, Ph.D., Pfizer, Inc., A
11:30 AM - 12:15 PM
Panel Discussion (including all speakers)
Donald A. Berry, Ph.D.,
Thomas G. Tensfeldt, M.S., Pfizer Global R&D,
Oncology Drug Development
Dinesh De Alwis, Ph.D., Eli Lilly & Company Ltd., Windlesham,
J. Robert Powell, Pharm.D., FCP, Food and Drug Administration,
Panel Discussion (including all speakers) 
Sandra Allerheiligen, Director, Drug Disposition - ADME and Global PK/PD, Eli Lilly, Indianapolis, IN Richard L. Lalonde, Pharm.D., FCP, VIce President & Global Head of Clinical Pharmacology, Pfizer Global R & D, New London, CT Andrew M. Dahlem, Ph.D., Vice President, Operations, Lilly Research Laboratories, Indianapolis, IN Lise Lund Kjems, M.D., Ph.D., Senior Director Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA Kathleen Giacomini, Ph.D., Professor and Chair, Dept. of Pharmaceutical Sciences, University of California, San Francisco, San Francisco, CA Rebecca Boyd, Ph.D., Senior Director in Cardiovascular/Metabolic Disease , Pfizer Global Research and Development, Groton, CT Donald A. Berry, Ph.D., Head and Chair, Division of Quantitative Sciences, MD Anderson Cancer Center, Houston, TX Thomas G. Tensfeldt, M.S., Director, Global Pharmacometrics Department, Pfizer Global Research & Development, Groton, CT Dinesh De Alwis, Ph.D., Head, PK/PD and Trial Simulation Group, Eli Lilly & Co., Windlesham, Surrey, UK J. Robert Powell, Pharm.D., FCP, Associate Director for Science, Office of Translational Sc., Food and Drug Administration, Silver Spring, MD
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
